Trials / Terminated
TerminatedNCT03592264
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- OBI Pharma, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OBI-3424 | liquid formulation for Intravenous infusion |
Timeline
- Start date
- 2018-07-02
- Primary completion
- 2024-02-13
- Completion
- 2024-03-21
- First posted
- 2018-07-19
- Last updated
- 2024-10-15
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03592264. Inclusion in this directory is not an endorsement.